Published in Matrix Biol on June 01, 1999
Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford) (2009) 1.24
Effects of short-term glucocorticoid treatment on changes in cartilage matrix degradation and chondrocyte gene expression induced by mechanical injury and inflammatory cytokines. Arthritis Res Ther (2011) 1.19
Analysing the role of endogenous matrix molecules in the development of osteoarthritis. Int J Exp Pathol (2009) 1.13
The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis (2010) 0.92
Production of interleukin-1 receptor antagonist by human articular chondrocytes. Arthritis Res (2002) 0.90
Interleukin-6 is elevated in synovial fluid of patients with focal cartilage defects and stimulates cartilage matrix production in an in vitro regeneration model. Arthritis Res Ther (2012) 0.89
Effects of insulin-like growth factor-1 and dexamethasone on cytokine-challenged cartilage: relevance to post-traumatic osteoarthritis. Osteoarthritis Cartilage (2014) 0.81
Effects of corticosterone on the metabolic activity of cultured chicken chondrocytes. BMC Vet Res (2015) 0.75
Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med (1985) 8.16
Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA (1999) 7.37
Production of collagenase and prostaglandins by isolated adherent rheumatoid synovial cells. Proc Natl Acad Sci U S A (1976) 5.40
Stimulation of rheumatoid synovial cell collagenase and prostaglandin production by partially purified lymphocyte-activating factor (interleukin 1). Proc Natl Acad Sci U S A (1981) 4.89
Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med (1988) 4.69
Two alternative job stress models and the risk of coronary heart disease. Am J Public Health (1998) 4.59
Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum (1990) 4.39
CCR5 is characteristic of Th1 lymphocytes. Nature (1998) 3.92
Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum (1995) 3.83
Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells. J Clin Invest (1986) 3.43
Participation of monocyte-macrophages and lymphocytes in the production of a factor that stimulates collagenase and prostaglandin release by rheumatoid synovial cells. J Clin Invest (1979) 3.34
Collagenase production by rheumatoid synovial cells: stimulation by a human lymphocyte factor. Science (1977) 2.91
Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages. J Exp Med (1984) 2.78
Low status control, high effort at work and ischemic heart disease: prospective evidence from blue-collar men. Soc Sci Med (1990) 2.63
Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis (2000) 2.59
Prostaglandin production by rheumatoid synovial cells: stimulation by a factor from human mononuclear Cells. J Exp Med (1977) 2.47
Antibiotic prophylaxis before invasive dental procedures in patients with arthroplasties of the hip and knee. J Bone Joint Surg Br (2008) 2.35
Purification of a factor from human blood monocyte-macrophages which stimulates the production of collagenase and prostaglandin E2 by cells cultured from rheumatoid synovial tissues. FEBS Lett (1981) 2.27
Job strain, effort-reward imbalance and employee well-being: a large-scale cross-sectional study. Soc Sci Med (2000) 2.24
A urine inhibitor of interleukin 1 activity that blocks ligand binding. J Immunol (1987) 2.17
Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine (2000) 2.11
Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. J Biol Chem (1989) 2.07
High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis (1992) 2.05
Relation between tumor necrosis factor-alpha and granulocyte elastase-alpha 1-proteinase inhibitor complexes in the plasma of patients with cystic fibrosis. Am Rev Respir Dis (1989) 1.99
Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol (1998) 1.97
Clonidine combined with a long acting local anesthetic does not prolong postoperative analgesia after brachial plexus block but does induce hemodynamic changes. Anesth Analg (2001) 1.91
Purification and characterization of human interleukin-1 beta expressed in recombinant Escherichia coli. Eur J Biochem (1986) 1.89
Incidence of hip fracture over a 10-year period (1991-2000): reversal of a secular trend. Bone (2007) 1.88
A human inhibitor of tumor necrosis factor alpha. J Exp Med (1988) 1.85
Increased prostaglandin production by human monocytes after membrane receptor activation. J Immunol (1979) 1.77
Celecoxib versus ibuprofen in the prevention of heterotopic ossification following total hip replacement: a prospective randomised trial. J Bone Joint Surg Br (2007) 1.72
Synthesis of interleukin 1/endogenous pyrogen in the brain of endotoxin-treated mice: a step in fever induction? J Immunol (1984) 1.71
Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s). J Clin Invest (1986) 1.70
Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol (1998) 1.70
Interleukin 1 is present in normal human epidermis. J Immunol (1986) 1.70
IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest (1995) 1.69
Induction of human interleukin 1 mRNA measured by collagenase- and prostaglandin E2-stimulating activity in rheumatoid synovial cells. Eur J Immunol (1984) 1.66
Purified blood monocytes from HIV 1-infected patients produce high levels of TNF alpha and IL-1. Clin Immunol Immunopathol (1989) 1.63
IFN-gamma and 1,25(OH)2D3 induce on THP-1 cells distinct patterns of cell surface antigen expression, cytokine production, and responsiveness to contact with activated T cells. J Immunol (1992) 1.62
Thyroid dysfunction in patients with diabetes: clinical implications and screening strategies. Int J Clin Pract (2010) 1.60
Serotonin syndrome after concomitant treatment with linezolid and citalopram. Clin Infect Dis (2003) 1.60
Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br J Rheumatol (1997) 1.57
Crucial role of tumor necrosis factor (TNF) receptor 2 and membrane-bound TNF in experimental cerebral malaria. Eur J Immunol (1997) 1.56
Peer review. Bone Joint J (2014) 1.54
Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system. J Bone Joint Surg Br (1999) 1.52
Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production. J Immunol (1990) 1.48
Survival and potential years of life lost after hip fracture in men and age-matched women. Osteoporos Int (2002) 1.47
Macrophage inflammatory protein-1: a prostaglandin-independent endogenous pyrogen. Science (1989) 1.46
Reference values and early determinants of intra-abdominal fat mass in primary school children. Horm Res Paediatr (2011) 1.46
Cytokines and other mediators in rheumatoid arthritis. Springer Semin Immunopathol (1984) 1.45
A urine inhibitor of interleukin 1 activity affects both interleukin 1 alpha and 1 beta but not tumor necrosis factor alpha. J Immunol (1987) 1.44
Lower limb trauma with injury to the popliteal vessels. J Trauma (1996) 1.42
Spondylodiscitis due to Propionibacterium acnes: report of twenty-nine cases and a review of the literature. Clin Microbiol Infect (2009) 1.41
Comparison of the outcome following the fixation of osteotomies or fractures associated with total hip replacement using cables or wires: the results at five years. J Bone Joint Surg Br (2012) 1.41
Does the addition of morphine to brachial plexus block improve analgesia after shoulder surgery? Br J Anaesth (1995) 1.40
[Acute compartment syndrome in the post-traumatic leg]. Rev Chir Orthop Reparatrice Appar Mot (1998) 1.40
Chronic work stress is associated with atherogenic lipids and elevated fibrinogen in middle-aged men. J Intern Med (1997) 1.38
Blunt injury to the subclavian or axillary artery. J Am Coll Surg (1994) 1.38
Suppression of metalloproteinase biosynthesis in human alveolar macrophages by interleukin-4. J Clin Invest (1992) 1.38
Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression. J Biol Chem (1994) 1.36
Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol (1997) 1.32
Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor. Proc Natl Acad Sci U S A (1990) 1.30
Imbalance between interstitial collagenase and tissue inhibitor of metalloproteinases 1 in synoviocytes and fibroblasts upon direct contact with stimulated T lymphocytes: involvement of membrane-associated cytokines. Arthritis Rheum (1998) 1.30
Limited effects of recombinant human and murine interleukin 1 and tumour necrosis factor on production of acute phase proteins by cultured rat hepatocytes. Biochem Int (1987) 1.30
The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis. Arthritis Rheum (2000) 1.29
Matrix metalloproteinases and TIMP in acute respiratory distress syndrome. Am J Respir Crit Care Med (1996) 1.29
Purification and characterization of human interleukin-1 alpha produced in Escherichia coli. Eur J Biochem (1987) 1.28
Growth factor responsiveness of human articular chondrocytes in aging and development. Arthritis Rheum (1995) 1.27
Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1 beta by monocytic cells: a possible role of CD69. Eur Cytokine Netw (1993) 1.26
Killing of Staphylococcus aureus by tumor necrosis factor-alpha-activated neutrophils. The role of serum opsonins, integrin receptors, respiratory burst, and degranulation. J Immunol (1993) 1.25
Interactions among rheumatoid synovial cells and monocyte-macrophages: production of collagenase-stimulating factor by human monocytes exposed to concanavalin A or immunoglobulin Fc fragments. J Immunol (1980) 1.24
Income, occupational position, qualification and health inequalities--competing risks? (comparing indicators of social status). J Epidemiol Community Health (2000) 1.24
The functional importance of a cap site-proximal region of the human prointerleukin 1 beta gene is defined by viral protein trans-activation. Mol Cell Biol (1992) 1.24
Interferon-beta not only inhibits interleukin-1beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. Eur Cytokine Netw (1997) 1.23
Mononuclear cell-conditioned medium containing mononuclear cell factor (MCF), homologous with interleukin 1, stimulates collagen and fibronectin synthesis by adherent rheumatoid synovial cells: effects of prostaglandin E2 and indomethacin. Coll Relat Res (1985) 1.22
Localization of [3H]ouabain-sensitive Na+ pump sites in cultured pig kidney cells. Am J Physiol (1979) 1.19
Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis. Lancet (1987) 1.19
Human Th1 cells preferentially induce interleukin (IL)-1beta while Th2 cells induce IL-1 receptor antagonist production upon cell/cell contact with monocytes. Eur J Immunol (1997) 1.18
Procalcitonin, IL-6, IL-8, IL-1 receptor antagonist and C-reactive protein as identificators of serious bacterial infections in children with fever without localising signs. Eur J Pediatr (2001) 1.18
Modulation of endotoxic activity of lipopolysaccharide by high-density lipoprotein. Pathobiology (1991) 1.17
Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. The J5 Study Group. Immunology (1992) 1.16
The insulin receptor of a human monocyte-like cell line: characterization and function. Endocrinology (1984) 1.16
Pulsatile non-Newtonian blood flow simulation through a bifurcation with an aneurysm. Biorheology (1989) 1.16
An osteoporosis clinical pathway for the medical management of patients with low-trauma fracture. Osteoporos Int (2002) 1.15
Production of monoclonal antibodies against interleukin-1 alpha and -1 beta. Development of two enzyme immunometric assays (EIA) using acetylcholinesterase and their application to biological media. J Immunol Methods (1989) 1.15
The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J Clin Invest (1995) 1.15
Rheumatoid synovial cell morphologic changes induced by a mononuclear cell factor in culture. Arthritis Rheum (1983) 1.14
Induction of plasma inhibitors of interleukin 1 and TNF-alpha activity by endotoxin administration to normal humans. Am J Physiol (1990) 1.14
Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study. Rheumatology (Oxford) (2001) 1.14
A cell strain cultured from porcine kidney increases cyclic AMP content upon exposure to calcitonin or vasopressin. Biochem Biophys Res Commun (1978) 1.14
Prognosis of functional recovery 1 year after hip fracture: typical patient profiles through cluster analysis. J Gerontol A Biol Sci Med Sci (2000) 1.14
Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. J Rheumatol (1997) 1.13
Inhibition by retinoic acid of collagenase production in rheumatoid synovial cells. N Engl J Med (1980) 1.12
Successful treatment of polyarteritis nodosa related to hepatitis B virus with a combination of lamivudine and interferon alpha. Rheumatology (Oxford) (1999) 1.12
Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response. Arthritis Rheum (1994) 1.12
Research findings linking workplace factors to CVD outcomes. Occup Med (2000) 1.11
Purification and characterization of a 26-kDa competitive inhibitor of interleukin 1. Eur J Immunol (1990) 1.10